Literature DB >> 22311171

Microevolution of Pseudomonas aeruginosa to a chronic pathogen of the cystic fibrosis lung.

Michael Hogardt1, Jürgen Heesemann.   

Abstract

Pseudomonas aeruginosa is the leading pathogen of chronic cystic fibrosis (CF) lung infection. Life-long persistance of P. aeruginosa in the CF lung requires a sophisticated habitat-specific adaptation of this pathogen to the heterogeneous and fluctuating lung environment. Due to the high selective pressure of inflamed CF lungs, P. aeruginosa increasingly experiences complex physiological and morphological changes. Pulmonary adaptation of P. aeruginosa is mediated by genetic variations that are fixed by the repeating interplay of mutation and selection. In this context, the emergence of hypermutable phenotypes (mutator strains) obviously improves the microevolution of P. aeruginosa to the diverse microenvironments of the CF lung. Mutator phenotypes are amplified during CF lung disease and accelerate the intraclonal diversification of P. aeruginosa. The resulting generation of numerous subclonal variants is advantegous to prepare P. aeruginosa population for unpredictable stresses (insurance hypothesis) and thus supports long-term survival of this pathogen. Oxygen restriction within CF lung environment further promotes persistence of P. aeruginosa due to increased antibiotic tolerance, alginate production and biofilm formation. Finally, P. aeruginosa shifts from an acute virulent pathogen of early infection to a host-adapted chronic virulent pathogen of end-stage infection of the CF lung. Common changes that are observed among chronic P. aeruginosa CF isolates include alterations in surface antigens, loss of virulence-associated traits, increasing antibiotic resistances, the overproduction of the exopolysaccharide alginate and the modulation of intermediary and micro-aerobic metabolic pathways (Hogardt and Heesemann, Int J Med Microbiol 300(8):557-562, 2010). Loss-of-function mutations in mucA and lasR genes determine the transition to mucoidity and loss of quorum sensing, which are hallmarks of the chronic virulence potential of P. aeruginosa. Metabolic factors that are positively selected in response to the specific environment of CF lung include the outer membrane protein OprF, the microaerophilic oxidase Cbb3-2, the blue copper protein azurin, the cytochrome c peroxidase c551 and the enzymes of the arginine deiminase pathway ArcA-ArcD. These metabolic adaptations probably support the growth of P. aeruginosa within oxygen-depleted CF mucus. The deeper understanding of the physiological mechanisms of niche specialization of P. aeruginosa during CF lung infection will help to identify new targets for future anti-pseudomonal treatment strategies to prevent the selection of mutator isolates and the establishment of chronic CF lung infection.

Entities:  

Mesh:

Year:  2013        PMID: 22311171     DOI: 10.1007/82_2011_199

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  63 in total

1.  Deletion mutant library for investigation of functional outputs of cyclic diguanylate metabolism in Pseudomonas aeruginosa PA14.

Authors:  Dae-Gon Ha; Megan E Richman; George A O'Toole
Journal:  Appl Environ Microbiol       Date:  2014-03-21       Impact factor: 4.792

Review 2.  Pseudomonas aeruginosa AmpR: an acute-chronic switch regulator.

Authors:  Deepak Balasubramanian; Hansi Kumari; Kalai Mathee
Journal:  Pathog Dis       Date:  2015-02-26       Impact factor: 3.166

3.  Dimeric c-di-GMP is required for post-translational regulation of alginate production in Pseudomonas aeruginosa.

Authors:  John C Whitney; Gregory B Whitfield; Lindsey S Marmont; Patrick Yip; A Mirela Neculai; Yuri D Lobsanov; Howard Robinson; Dennis E Ohman; P Lynne Howell
Journal:  J Biol Chem       Date:  2015-03-27       Impact factor: 5.157

4.  Pseudomonas aeruginosa utilizes host polyunsaturated phosphatidylethanolamines to trigger theft-ferroptosis in bronchial epithelium.

Authors:  Haider H Dar; Yulia Y Tyurina; Karolina Mikulska-Ruminska; Indira Shrivastava; Hsiu-Chi Ting; Vladimir A Tyurin; James Krieger; Claudette M St Croix; Simon Watkins; Erkan Bayir; Gaowei Mao; Catherine R Armbruster; Alexandr Kapralov; Hong Wang; Matthew R Parsek; Tamil S Anthonymuthu; Abiola F Ogunsola; Becca A Flitter; Cody J Freedman; Jordan R Gaston; Theodore R Holman; Joseph M Pilewski; Joel S Greenberger; Rama K Mallampalli; Yohei Doi; Janet S Lee; Ivet Bahar; Jennifer M Bomberger; Hülya Bayır; Valerian E Kagan
Journal:  J Clin Invest       Date:  2018-09-10       Impact factor: 14.808

Review 5.  Clinical Significance and Pathogenesis of Staphylococcal Small Colony Variants in Persistent Infections.

Authors:  Barbara C Kahl; Karsten Becker; Bettina Löffler
Journal:  Clin Microbiol Rev       Date:  2016-04       Impact factor: 26.132

6.  Pseudomonas aeruginosa and Periodontal Pathogens in the Oral Cavity and Lungs of Cystic Fibrosis Patients: a Case-Control Study.

Authors:  Rocio Rivas Caldas; Florence Le Gall; Krista Revert; Gilles Rault; Michèle Virmaux; Stephanie Gouriou; Geneviève Héry-Arnaud; Georges Barbier; Sylvie Boisramé
Journal:  J Clin Microbiol       Date:  2015-04-08       Impact factor: 5.948

Review 7.  Pouring salt on a wound: Pseudomonas aeruginosa virulence factors alter Na+ and Cl- flux in the lung.

Authors:  Alicia E Ballok; George A O'Toole
Journal:  J Bacteriol       Date:  2013-07-08       Impact factor: 3.490

8.  Pseudomonas toxin pyocyanin triggers autophagy: Implications for pathoadaptive mutations.

Authors:  Zhong-Shan Yang; Lan-Qing Ma; Kun Zhu; Jin-Yuan Yan; Li Bian; Ke-Qin Zhang; Cheng-Gang Zou
Journal:  Autophagy       Date:  2016-05-09       Impact factor: 16.016

9.  Epoxide-mediated CifR repression of cif gene expression utilizes two binding sites in Pseudomonas aeruginosa.

Authors:  Alicia E Ballok; Christopher D Bahl; Emily L Dolben; Allia K Lindsay; Jessica D St Laurent; Deborah A Hogan; Dean R Madden; George A O'Toole
Journal:  J Bacteriol       Date:  2012-07-27       Impact factor: 3.490

Review 10.  Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin.

Authors:  Zarmina Ehsan; John P Clancy
Journal:  Future Microbiol       Date:  2015-11-17       Impact factor: 3.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.